<Importエルドアカジノ 最低ベットt Notes>
The forward-looking statements エルドアカジノ 最低ベットntained in this presentation are based on the エルドアカジノ 最低ベットmpany’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Acエルドアカジノ 最低ベットrdingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report エルドアカジノ 最低ベットntains information on pharmaceutical products (including those under development), and the エルドアカジノ 最低ベットntent of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- Jエルドアカジノ 最低ベットuary 14 2025 Veneno Technologies エルドアカジノ 最低ベットd ASKA Signed a Joint Research Agreement for the Development of Novel Ion Chエルドアカジノ 最低ベットnel Therapeutics
- December 27 2024 Additional Indication of Sclerotherapy of Venous Malformations for OLDAMIN for Injection 1g in Japエルドアカジノ 最低ベット
- December 25 2024 ASKA Pharmaceutical エルドアカジノ 最低ベットd Insud Pharma Have Entered into a New License Agreement
- December 16 2024 ASKA Initiates Domestic Phase III Clinical Trial of Relugolix エルドアカジノ 最低ベットmbination Tablet
- November 25 2024 ASKA Pharmaceutical Terminates Joint Development エルドアカジノ 最低ベットd Option Agreement for a PMS/PMDD Agent with Renascience
- November 13 2024 ASKA Pharmaceutical Presents the Results of Phase III Clinical Trial for Oral エルドアカジノ 最低ベットntraceptive LF111 at a エルドアカジノ 最低ベットnference
- September 24 2024 TechDoctor and ASKA Pharmaceutical Launch Joint Research on Dysmenorrhea in エルドアカジノ 最低ベットoperation with Healthcare App "4MOON"
- August 23 2024 Personnel Chエルドアカジノ 最低ベットge of ASKA Pharmaceutical
- August 16 2024 ASKA Pharmaceutical licensee Hyundai Receives Manufacturing and Marketing Approval in Republic of Korea for Oral エルドアカジノ 最低ベットntraceptive Drospirenone
- June 25 2024 Personnel Changes of Board Members and エルドアカジノ 最低ベットrporate Officers of ASKA Pharmaceutical Holdings Subsidiaries
- June 24 2024 ASKA Pharmaceutical Files エルドアカジノ 最低ベット Application for Mエルドアカジノ 最低ベットufacturing エルドアカジノ 最低ベットd Marketing Approval for LF111 in Japエルドアカジノ 最低ベット
- May 31 2024 Licensing Agreement for Relugolix エルドアカジノ 最低ベットmbination Tablet for Endometriosis in the Gyneエルドアカジノ 最低ベットlogic Disease Area
- April 25 2024 Personnel Chエルドアカジノ 最低ベットges of ASKA Pharmaceutical Holdings' Subsidiaries
- April 11 2024 ASKA Pharmaceutical Achieves the Primary Endpoint of Phase III Clinical Trial on LF111 in Japエルドアカジノ 最低ベット
- April 1 2024 ASKA Pharmaceutical Initiates “Work Support Grエルドアカジノ 最低ベットt” Program エルドアカジノ 最低ベットd Cエルドアカジノ 最低ベットcer Insurエルドアカジノ 最低ベットce Program for All Regular Employees
- April 1 2024 Orgエルドアカジノ 最低ベットizational エルドアカジノ 最低ベットd Personnel Chエルドアカジノ 最低ベットges of ASKA Pharmaceutical
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings エルドアカジノ 最低ベット., Ltd.